New pill could cut transfusions for thalassemia patients
NCT ID NCT06302491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests an oral drug called AND017 in 64 people with β-thalassemia, a blood disorder that often requires regular transfusions. Half the participants get the drug, half get a placebo, and everyone continues standard care. The goal is to see if AND017 is safe and can raise hemoglobin levels, potentially reducing transfusion needs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AND017 capsules
What this could lead to
If successful, AND017 could reduce the need for blood transfusions in people with β-thalassemia by boosting hemoglobin levels.
What could go wrong
This is an early Phase 2 trial with only 64 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangxi Medical University No.1 Affiliated Hospital
RECRUITINGNanning, Guangxi, 530021, China
Contact
-
Hainan General Hospital
RECRUITINGHaikou, Hainan, 570203, China
Contact
-
Liuzhou People's Hospital
RECRUITINGLiuzhou, Guangxi, 545006, China
Contact
-
Maoming People's Hospital
RECRUITINGMaoming, Guangdong, 525000, China
Contact
-
Nanfang Hospital Southern Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510515, China
Contact